Pitolisant
- Generic Name
- Pitolisant
- Brand Names
- Wakix, Ozawade
- Drug Type
- Small Molecule
- Chemical Formula
- C17H26ClNO
- CAS Number
- 362665-56-3
- Unique Ingredient Identifier
- 4BC83L4PIY
- Background
Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations. About 60-70% of pat...
- Indication
Pitolisant is indicated for the treatment of narcolepsy with or without cataplexy and excessive daytime sleepiness in narcolepsy in adult patients.
- Associated Conditions
- Excessive Daytime Sleepiness, Narcolepsy With Cataplexy, Narcolepsy Without Cataplexy
- Associated Therapies
- -
Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind Study Followed by a Prolonged Open-label Period
- Conditions
- Interventions
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Bioprojet
- Target Recruit Count
- 110
- Registration Number
- NCT02611687
- Locations
- 🇫🇷
Hôpital Femme-Mère-Enfant, Bron, France
🇳🇱Polikliniek Heemstede Neurologist-Somnologist, Heemstede, Netherlands
🇮🇹Università di Bologna, Bologna, Italy
Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP)
- Conditions
- Interventions
- First Posted Date
- 2013-02-27
- Last Posted Date
- 2016-08-31
- Lead Sponsor
- Bioprojet
- Target Recruit Count
- 103
- Registration Number
- NCT01800045
- Locations
- 🇭🇺
State Health Center, Budapest, Hungary
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.